NBNoelia Boldizsar

Noelia Boldizsar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Noelia Boldizsar has a total of 78 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    G Protein-Coupled Receptor Kinase 2 Selectively Enhances β-Arrestin Recruitment to the D2 Dopamine Receptor through Mechanisms That Are Independent of Receptor Phosphorylation

    by Marta Sánchez-Soto, Noelia M. Boldizsar, Kayla A. Schardien, Nora S. Madaras, Blair K. A. Willette, Laura R. Inbody, Christopher Dasaro, Amy E. Moritz, Julia Drube, Raphael S. Haider, et al.

    The D2 dopamine receptor (D2R) signals through both G proteins and β-arrestins to regulate important physiological processes, such as movement, reward circuitry, emotion, and cognition. β-arrestins are believed to interact with G protein-coupled receptors (GPCRs) at the phosphorylated C-terminal tail or intracellular loops. GPCR kinases (GRKs) are the primary drivers of GPCR phosphorylation, and for many receptors, receptor phosphorylation is indispensable for β-arrestin recruitment. However, GRK-mediated receptor phosphorylation is not required for β-arrestin recruitment to the D2R, and the role of GRKs in D2R–β-arrestin interactions remains largely unexplored. In this study, we used GRK knockout cells engineered using CRISPR-Cas9 technology to determine the extent to which β-arrestin recruitment to the D2R is GRK-dependent. Genetic elimination of all GRK expression decreased, but did not eliminate, agonist-stimulated β-arrestin recruitment to the D2R or its subsequent internalization. However, these processes were rescued upon the re-introduction of various GRK isoforms in the cells with GRK2/3 also enhancing dopamine potency. Further, treatment with compound 101, a pharmacological inhibitor of GRK2/3 isoforms, decreased β-arrestin recruitment and receptor internalization, highlighting the importance of this GRK subfamily for D2R–β-arrestin interactions. These results were recapitulated using a phosphorylation-deficient D2R mutant, emphasizing that GRKs can enhance β-arrestin recruitment and activation independently of receptor phosphorylation.


  • Open Access

    Pharmacology and Therapeutic Potential of Benzothiazole Analogues for Cocaine Use Disorder

    by Comfort A. Boateng, Ashley N. Nilson, Rebekah Placide, Mimi L. Pham, Franziska M. Jakobs, Noelia Boldizsar, Scot McIntosh, Leia S. Stallings, Ivana V. Korankyi, Shreya Kelshikar, et al.

    Pharmacological targeting of the dopamine D4 receptor (D4R)─expressed in brain regions that control cognition, attention, and decision-making─could be useful for several neuropsychiatric disorders including substance use disorders (SUDs). This study focused on the synthesis and evaluation of a novel series of benzothiazole analogues designed to target D4R. We identified several compounds with high D4R binding affinity (Ki ≤ 6.9 nM) and >91-fold selectivity over other D2-like receptors (D2R, D3R) with diverse partial agonist and antagonist profiles. Novel analogue 16f is a potent low-efficacy D4R partial agonist, metabolically stable in rat and human liver microsomes, and has excellent brain penetration in rats (AUCbrain/plasma > 3). 16f (5-30 mg/kg, i.p.) dose-dependently decreased iv cocaine self-administration in rats, consistent with previous results produced by D4R-selective antagonists. Off-target antagonism of 5-HT2A or 5-HT2B may also contribute to these effects. Results with 16f support further efforts to target D4R in SUD treatment.


  • Open Access

    GRK2 Enhances ß-arrestin Recruitment to the D2 Dopamine Receptor Through a Mechanism that is Independent From Receptor Phosphorylation or G Protein Activation

    by Noelia Boldizsar, Marta Sanchez-Soto, Julia Drube, Raphael Haider, R Benjamin Free, Carsten Hoffman, David R. Sibley

    ID 19401 Poster Board 148 The D2 dopamine receptor (D2R) interacts with and signals through both G proteins and ss-arrestins to regulate important physiological processes, such as movement, reward circuitry, emotion, and cognition. ß-arrestins are believed to interact with G protein-coupled receptors (GPCRs) at two interfaces: the receptor core and the phosphorylated C-terminal tail or intracellular loops. GPCR kinases (GRKs) are the primary drivers of GPCR phosphorylation, and for many receptors, this post-translational modification is indispensable for ß-arrestin recruitment. However, GRK-mediated receptor phosphorylation is not required for ß-arrestin recruitment to the D2R, and the role of GRKs in D2R-ß-arrestin interactions remains largely unexplored. In this study, we used GRK knockout cells engineered using CRISPR-Cas9 technology to determine if ß-arrestin recruitment to the D2R was GRK-dependent. Genetic elimination of all GRK expression significantly decreased, but did not totally eliminate, both ß-arrestin recruitment to the D2R and receptor internalization. However, these processes were rescued upon re-introduction of various GRK isoforms in the cells via transient transfection. Further, treatment with compound 101, a pharmacological inhibitor of GRK2/3 isoforms, dose-dependently decreased ß-arrestin recruitment and receptor internalization, highlighting the importance of these kinases for D2R-ß-arrestin interactions. Interestingly, these results were recapitulated using a phosphorylation-deficient (PO4-null) D2R mutant, emphasizing that GRKs enhance D2R-ß-arrestin interactions independently from receptor phosphorylation. As GRK2/3 are well known to interact with the ß-γ subunits of G proteins following heterotrimer dissociation, we investigated the role of G proteins in GRK functionality at the D2R. Inhibition of G protein signaling with pertussis toxin modestly decreased ß-arrestin recruitment to the D2R in cells expressing endogenous amounts of GRKs but had no effect when GRK2 was overexpressed. We also used a mutant GRK2 that is unable to bind to ß-γ G protein subunits (GRK2-R587Q) and found that ß-γ interactions were not necessary for this function of GRK2. Next, we investigated if the catalytic activity of GRK2 is required to enhance D2R-ß-arrestin interactions. Overexpression of a catalytically inactive GRK2 mutant (GRK2-K220R) did not enhance ß-arrestin recruitment or receptor internalization in cells expressing endogenous amounts of GRKs. However, when transfected into GRK-KO cells, GRK2-K220R rescued ß-arrestin recruitment and D2R internalization, albeit to a slightly lesser extent than WT GRK2. However, we found that GRK2-K220R is recruited to the D2R less efficiently than WT GRK2 in both parental and GRK-KO cells. Therefore, its lack of effect when overexpressed in parental cells could be due to competition from endogenous GRKs. Further, the reduced ability of GRK2-K220R to interact with the D2R could explain its reduced ability to drive ß-arrestin recruitment compared to WT GRK2. In summary, we demonstrate that GRKs, especially GRK2/3, are necessary for maximal agonist-stimulated D2R-ß-arrestin interactions, however, their kinase activities are not required. We hypothesize that GRK2 might act through a novel non-catalytic, scaffolding mechanism to enhance ß-arrestin recruitment to the D2R, highlighting the diversity with which GPCRs can interact with signal transduction proteins.


  • Identification and Characterization of ML321: A Novel and Highly Selective D2 Dopamine Receptor Antagonist with Efficacy in Animal Models That Predict Atypical Antipsychotic Activity

    by R. Benjamin Free, Ashley N. Nilson, Noelia M. Boldizsar, Trevor B. Doyle, Ramona M. Rodriguiz, Vladimir M. Pogorelov, Mayako Machino, Kuo Hao Lee, Jeremiah W. Bertz, Jinbin Xu, et al.

    We have developed and characterized a novel D2R antagonist with exceptional GPCR selectivity - ML321. In functional profiling screens of 168 different GPCRs, ML321 showed little activity beyond potent inhibition of the D2R and to a lesser extent the D3R, demonstrating excellent receptor selectivity. The D2R selectivity of ML321 may be related to the fact that, unlike other monoaminergic ligands, ML321 lacks a positively charged amine group and adopts a unique binding pose within the orthosteric binding site of the D2R. PET imaging studies in non-human primates demonstrated that ML321 penetrates the CNS and occupies the D2R in a dose-dependent manner. Behavioral paradigms in rats demonstrate that ML321 can selectively antagonize a D2R-mediated response (hypothermia) while not affecting a D3R-mediated response (yawning) using the same dose of drug, thus indicating exceptional in vivo selectivity. We also investigated the effects of ML321 in animal models that are predictive of antipsychotic efficacy in humans. We found that ML321 attenuates both amphetamine- and phencyclidine-induced locomotor activity and restored pre-pulse inhibition (PPI) of acoustic startle in a dose-dependent manner. Surprisingly, using doses that were maximally effective in both the locomotor and PPI studies, ML321 was relatively ineffective in promoting catalepsy. Kinetic studies revealed that ML321 exhibits slow-on and fast-off receptor binding rates, similar to those observed with atypical antipsychotics with reduced extrapyramidal side effects. Taken together, these observations suggest that ML321, or a derivative thereof, may exhibit ″atypical″ antipsychotic activity in humans with significantly fewer side effects than observed with the currently FDA-approved D2R antagonists.


  • Biased agonists of the chemokine receptor CXCR3 differentially signal through Gα i :β-arrestin complexes

    by Kevin Zheng, Jeffrey S. Smith, Dylan S. Eiger, Anmol Warman, Issac Choi, Christopher C. Honeycutt, Noelia Boldizsar, Jaimee N. Gundry, Thomas F. Pack, Asuka Inoue, et al.

    G protein–coupled receptors (GPCRs) are the largest family of cell surface receptors and signal through the proximal effectors, G proteins and β-arrestins, to influence nearly every biological process. The G protein and β-arrestin signaling pathways have largely been considered separable; however, direct interactions between Gα proteins and β-arrestins have been described that appear to be part of a distinct GPCR signaling pathway. Within these complexes, Gα i/o , but not other Gα protein subtypes, directly interacts with β-arrestin, regardless of the canonical Gα protein that is coupled to the GPCR. Here, we report that the endogenous biased chemokine agonists of CXCR3 (CXCL9, CXCL10, and CXCL11), together with two small-molecule biased agonists, differentially formed Gα i :β-arrestin complexes. Formation of the Gα i :β-arrestin complexes did not correlate well with either G protein activation or β-arrestin recruitment. β-arrestin biosensors demonstrated that ligands that promoted Gα i :β-arrestin complex formation generated similar β-arrestin conformations. We also found that Gα i :β-arrestin complexes did not couple to the mitogen-activated protein kinase ERK, as is observed with other receptors such as the V2 vasopressin receptor, but did couple with the clathrin adaptor protein AP-2, which suggests context-dependent signaling by these complexes. These findings reinforce the notion that Gα i :β-arrestin complex formation is a distinct GPCR signaling pathway and enhance our understanding of the spectrum of biased agonism.


  • Open Access

    Location bias contributes to functionally selective responses of biased CXCR3 agonists

    by Dylan Scott Eiger, Noelia Boldizsar, Christopher Cole Honeycutt, Julia Gardner, Stephen Kirchner, Chloe Hicks, Issac Choi, Uyen Pham, Kevin Zheng, Anmol Warman, et al.

    SUMMARY: Some G protein-coupled receptor (GPCR) ligands act as “biased agonists” which preferentially activate specific signaling transducers over others. Although GPCRs are primarily found at the plasma membrane, GPCRs can traffic to and signal from many subcellular compartments. Here, we determine that differential subcellular signaling contributes to the biased signaling generated by three endogenous ligands of the chemokine GPCR CXCR3. The signaling profile of CXCR3 changed as it trafficked from the plasma membrane to endosomes in a ligand-specific manner. Endosomal signaling was critical for biased activation of G proteins, β-arrestins, and ERK1/2. In CD8+ T cells, the chemokines promoted unique transcriptional responses predicted to regulate inflammatory pathways. In a mouse model of contact hypersensitivity, β-arrestin-biased CXCR3-mediated inflammation was dependent on receptor internalization. Our work demonstrates that differential subcellular signaling is critical to the overall biased response observed at CXCR3, which has important implications for drugs targeting chemokine receptors and other GPCRs.